Header

UZH-Logo

Maintenance Infos

Interleukin-2 and regulatory T cells in rheumatic diseases


Kolios, Antonios G A; Tsokos, George C; Klatzmann, David (2021). Interleukin-2 and regulatory T cells in rheumatic diseases. Nature reviews. Rheumatology, 17(12):749-766.

Abstract

Failure of regulatory T (Treg) cells to properly control immune responses leads invariably to autoimmunity and organ damage. Decreased numbers or impaired function of Treg cells, especially in the context of inflammation, has been documented in many human autoimmune diseases. Restoration of Treg cell fitness and/or expansion of their numbers using low-dose natural IL-2, the main cytokine driving Treg cell survival and function, has demonstrated clinical efficacy in early clinical trials. Genetically modified IL-2 with an extended half-life and increased selectivity for Treg cells is now in clinical development. Administration of IL-2 combined with therapies targeting other pathways involved in the expression of autoimmune diseases should further enhance its therapeutic potential. Ongoing clinical efforts that capitalize on the early clinical success of IL-2 treatment should bring the use of this cytokine to the forefront of biological treatments for autoimmune diseases.

Abstract

Failure of regulatory T (Treg) cells to properly control immune responses leads invariably to autoimmunity and organ damage. Decreased numbers or impaired function of Treg cells, especially in the context of inflammation, has been documented in many human autoimmune diseases. Restoration of Treg cell fitness and/or expansion of their numbers using low-dose natural IL-2, the main cytokine driving Treg cell survival and function, has demonstrated clinical efficacy in early clinical trials. Genetically modified IL-2 with an extended half-life and increased selectivity for Treg cells is now in clinical development. Administration of IL-2 combined with therapies targeting other pathways involved in the expression of autoimmune diseases should further enhance its therapeutic potential. Ongoing clinical efforts that capitalize on the early clinical success of IL-2 treatment should bring the use of this cytokine to the forefront of biological treatments for autoimmune diseases.

Statistics

Citations

Dimensions.ai Metrics
56 citations in Web of Science®
57 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

3 downloads since deposited on 06 Dec 2021
0 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Dermatology Clinic
Dewey Decimal Classification:610 Medicine & health
Scopus Subject Areas:Health Sciences > Rheumatology
Language:English
Date:December 2021
Deposited On:06 Dec 2021 04:53
Last Modified:26 Jun 2024 01:45
Publisher:Nature Publishing Group
ISSN:1759-4790
OA Status:Closed
Publisher DOI:https://doi.org/10.1038/s41584-021-00707-x
PubMed ID:34728817